Landos Biopharma teams up with LianBio for $218M-plus collab and sales deal for 2 immunology assets in Asia

Drug licenser LianBio and recently IPO’d autoimmune biotech Landos Biopharma are joining forces to develop and sell two ulcerative colitis (UC) and Crohn’s disease (CD) assets in China and parts of Asia.